We Are the Best Choice

CD BioGlyco supports the research of emerging viral Vaccines. The recombinant glycoprotein we provide for vaccine development is used for the novel vaccine recombinant glycoprotein vaccine and this type of vaccine has the following advantages:

• These vaccines are obtained using genetic engineering technology. This technology allows to cloning of the protective antigenic genes of pathogens. It also modifies them in vitro to optimize their immunogenicity.
• The transfer of immunogenic protein genes into heterologous biological hosts or cultured cells allows for the expression of pathogen proteins in large quantities.
• These vaccines are simple, reducing or eliminating pyrogens, and other harmful reactants that are difficult to avoid with conventional vaccines.
• These vaccines cannot replicate in the body and pose no risk of pathogenicity to the host, providing safety and stability.
• The transfer of immunogenic protein genes from highly dangerous pathogens to non-pathogenic and harmless microorganisms for expression adds to the safety of the vaccine.
• These vaccines can be used for pathogens that cannot be cultured in vitro, expanding the scope of vaccine use.

Fig.1 Benefits of the recombinant glycoprotein vaccine. (CD BioGlyco)

We offer vaccine development services based on a wide range of viral glycoproteins. The process includes the following steps.

• We identify pathogen-specific proteins that are immunogenic.
• We integrate pathogen-specific protein genes into suitable expression systems (Yeast, Escherichia coli, Plant, Mammals, etc.) through genetic engineering methods.
• We optimize culture conditions and purification methods to express pathogen-specific proteins through in vitro mass culture.
• We screen for suitable adjuvants and finally prepare the vaccine.
• We test the effectiveness of vaccines.

Fig.2 Process of recombinant glycoprotein vaccine development. (CD BioGlyco)

Applications of Recombinant Glycoprotein Vaccine

• Monoclonal antibodies are used for immunological characterization of pathogens and their specific antibodies. Our recombinant glycoprotein vaccine development services include the production of recombinant glycoproteins, which can be used for antibody production.
• The recombinant glycoprotein vaccines can be also used to study their efficacy in combination with other vaccines.

Highlights of Us

• We have a wide range of exogenous protein expression systems to choose, including yeast expression systems, E. coli expression systems, baculovirus expression systems, etc.
• We provide one-stop vaccine development services, including a full set of experiments from vaccine design, and production, to safety evaluation.

CD BioGlyco has a state-of-the-art technology platform and expertise in vaccine development. We aim to help our clients accelerate the vaccine research process. In addition to recombinant glycoprotein vaccines, we also offer Carbohydrate-based Vaccine and Glycopeptide-based Vaccine development services. Feel free to contact us for recombinant glycoprotein vaccine development solutions.

Reference

1. Strasser, R. Plant glycoengineering for designing next-generation vaccines and therapeutic proteins. Biotechnol Adv. 2023, 67: 108197.

Quick Links

Resources